Pyridoxal-5'-phosphate: A cost-effective treatment candidate for hypertensive patients?
- PMID: 39385670
- DOI: 10.1111/joim.20015
Pyridoxal-5'-phosphate: A cost-effective treatment candidate for hypertensive patients?
Abstract
Objectives: Because angiotensin (Ang) II is an essential vasoconstrictive peptide, we analyzed the impact of its post-translational modification to pyruvamide-Ang II (Ang P) by pyridoxal-5'-phosphate (PLP) on blood pressure. PLP is a less expensive vitamin B6 derivative and, therefore, could be a cost-effective drug against hypertension.
Methods: Effect of Ang P on calcium ion entry into vascular smooth muscle cells (VSMCs) was analyzed. Binding affinity of Ang P to angiotensin II type 1 receptor (AT1R) was measured. Vasoconstrictive effect of Ang P was investigated using the bioassay of isolated perfused rat kidneys. Spontaneously hypertensive rats (SHR) were administered PLP. Additionally, Wistar Kyoto rats (WKY) received Ang II and PLP. Blood pressure was measured time-dependently.
Results: Ang II, incubated with PLP, was post-translationally modified to Ang P. Calcium ion entry in VSMCs was significantly lower with Ang P compared to Ang II. Binding affinity of Ang P to AT1R was lower compared to Ang II. Perfusion pressure of isolated perfused rat kidneys increased less by Ang P than by Ang II. Blood pressure of SHR treated with PLP decreased significantly. Blood pressure of WKY rats treated with Ang II was increased to hypertensive values, whereas blood pressure of WKY rats cotreated with Ang II and PLP was not.
Conclusion: PLP induces a post-translational modification of Ang II decreasing blood pressure in rats. Assuming that increased PLP intake in the form of vitamin B6 might reduce blood pressure in hypertensive patients, PLP might be a cost-effective drug against hypertension.
Keywords: angiotensin II; hypertension; pyridoxal‐5′‐phosphate; pyruvamide–angiotensin II; renin–angiotensin–aldosterone system; vitamin B6.
© 2024 The Author(s). Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
References
-
- Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361–2371. https://doi.org/10.1016/j.jacc.2022.11.005
-
- Zhou B, Carrillo‐Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population‐representative studies with 104 million participants. The Lancet. 2021;398(10304):957–980. https://doi.org/10.1016/S0140‐6736(21)01330‐1.
-
- Otiti MI, Allen SJ. Severe acute malnutrition in low‐ and middle‐income countries. Paediatr Child Health. 2021;31(8):301–307. https://doi.org/10.1016/j.paed.2021.05.001.
-
- Yang ZW, Wei XB, Fu BQ, Chen JY, Yu DQ. Prevalence and prognostic significance of malnutrition in hypertensive patients in a community setting. Front Nutr. 2022;9:822376. Epub 2022/03/15. https://doi.org/10.3389/fnut.2022.822376.
-
- Gnugesser E, Chwila C, Brenner S, Deckert A, Dambach P, Steinert JI, et al. The economic burden of treating uncomplicated hypertension in sub‐Saharan Africa: a systematic literature review. BMC Public Health. 2022;22(1):1507. https://doi.org/10.1186/s12889‐022‐13877‐4.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous